更新于：2024-09-21
Upadacitinib hemihydrate
乌帕替尼
更新于：2024-09-21
概要
基本信息
药物类型 小分子化药 |
别名 Upadacitinib Hydrate、Upadacitinib tartrate、A-1293543.0 + [5] |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)、JAK3抑制剂(酪氨酸蛋白激酶JAK3抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国) |
登录后查看首次获批时间轴
结构
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
128
项与 乌帕替尼 相关的临床试验A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Application of the Personalized N-of-1 Trial Design in Patients with Rheumatoid Arthritis
Efficacy of Upadacitinib After Autologous Non-cultured Epidermal Cell Suspension Transplantation in Vitiligo Participants -- a Pilot, Random, Observer Blinded, Comparative Study
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
924
项与 乌帕替尼 相关的文献（医药）2025-04-01DEN open
Duodenitis associated with ulcerative colitis and pouchitis after total colectomy successfully treated with upadacitinib: A case report
Article
作者: Tezuka, Yukari ; Kojima, Kentaro ; Onishi, Sachiyo ; Shimizu, Masahito ; Masuda, Naoya ; Otani, Kiichi ; Takada, Jun ; Kubota, Masaya ; Ibuka, Takashi
Abstract:
A 27‐year‐old man had ulcerative colitis (UC) 1 year prior and underwent a colectomy and two‐stage ileal pouch‐anal anastomosis for medically refractory UC 6 months ago. He visited our department with epigastric pain and discomfort, increased stool frequency, and bloody diarrhea. Esophagogastroduodenoscopy revealed continuous diffuse friable mucosa, erosions, and edema in the duodenum, and pouchoscopy revealed multiple ulcers and purulent mucus adhesions. Based on endoscopic and pathological findings, the patient was diagnosed with duodenitis associated with UC and pouchitis, for which he received oral prednisolone (40 mg/day) and ciprofloxacin. The frequency of stools and occurrence of bloody diarrhea reduced, and epigastric pain and discomfort improved after 2 weeks. However, when prednisolone was discontinued, the symptoms worsened, albumin level decreased, and C‐reactive protein level increased. Following this, we administered a 20 mg prednisolone sodium phosphate enema once daily, and the patient's symptoms improved. However, the symptoms relapsed when the enema was discontinued. Assuming that the patient had steroid‐dependent duodenitis associated with UC and pouchitis, we initiated upadacitinib. His symptoms improved within a few days, and biomarkers returned to normal after 1 month. Nine months after initiating the upadacitinib treatment, endoscopic remission was achieved in the mucosa of the duodenum and pouch. The patient has been in clinical remission for 1 year without any adverse events.
2024-12-31The Journal of dermatological treatment
A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor
Article
作者: Zheng, Chunzhi ; Liu, Hong ; Zhou, Guizhi ; Yu, Yueqian
AIM:
This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).
METHODS:
We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.
RESULTS:
Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.
CONCLUSIONS:
JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.
2024-12-31The Journal of dermatological treatment
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
Article
作者: Hagino, Teppei ; Saeki, Hidehisa ; Fujimoto, Eita ; Kanda, Naoko
BACKGROUND:
Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).
OBJECTIVES:
To assess the effectiveness and safety of upadacitinib through 48 weeks in real-world clinical practice for Japanese AD patients (aged ≥12 years).
METHODS:
This retrospective study included 287 patients with moderate-to severe AD treated with 15 mg (n = 216) or 30 mg (n = 71) of upadacitinib daily. Effectiveness was assessed using eczema area severity index (EASI) scores, atopic dermatitis control tool (ADCT), peak pruritus-numerical rating scale (PP-NRS), and investigator's global assessment (IGA). Safety was evaluated through the incidence of treatment-emergent adverse events.
RESULTS:
From baseline, EASI, ADCT, PP-NRS, and IGA rapidly reduced at week 4, and the reduction was maintained until week 48 of treatment with upadacitinib at both doses. Achievement rates of EASI 75, EASI 90, and EASI 100 at week 48 were 63.5, 30.2, and 7.9 in 15 mg group, and 77.4, 54.8, and 3.2% in 30 mg group, respectively. Acne and herpes zoster were frequent, but no serious adverse events occurred.
CONCLUSIONS:
Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| AS | 欧盟 | 2019-12-16 | |
| AS | 冰岛 | 2019-12-16 | |
| AS | 列支敦士登 | 2019-12-16 | |
| AS | 挪威 | 2019-12-16 | |
| 银屑病关节炎 | 欧盟 | 2019-12-16 | |
| 银屑病关节炎 | 冰岛 | 2019-12-16 | |
| 银屑病关节炎 | 列支敦士登 | 2019-12-16 | |
| 银屑病关节炎 | 挪威 | 2019-12-16 | |
| AxSpA | 欧盟 | 2019-12-16 | |
| AxSpA | 冰岛 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 巨细胞动脉炎 | 申请上市 | 美国 | 2024-07-12 | |
| 巨细胞动脉炎 | 申请上市 | 欧盟 | 2024-07-12 | |
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 膚網製鬱積醖窪鑰選構(顧窪艱遞鹽願膚鏇鑰遞) = 壓獵觸鏇廠廠壓製餘餘 衊遞網窪鏇糧憲築夢範 (淵觸夢艱築繭夢範窪簾 ) 更多 | 积极 | 2024-09-04 | |||
Placebo | 膚網製鬱積醖窪鑰選構(顧窪艱遞鹽願膚鏇鑰遞) = 簾鑰簾網選夢淵齋鏇繭 衊遞網窪鏇糧憲築夢範 (淵觸夢艱築繭夢範窪簾 ) 更多 | ||||||
临床3期 | - | (Measure Up 1 and 2) | 淵衊壓鑰淵構糧製選餘(鏇選範餘憲積淵製觸醖) = 壓顧範構獵觸艱淵構壓 網齋築窪鬱觸窪鬱壓繭 (鹽顧憲鬱窪艱顧簾醖簾 ) 更多 | 积极 | 2024-08-07 | ||
Placebo (Measure Up 1 and 2) | 淵衊壓鑰淵構糧製選餘(鏇選範餘憲積淵製觸醖) = 積簾獵觸選鑰築鹽壓廠 網齋築窪鬱觸窪鬱壓繭 (鹽顧憲鬱窪艱顧簾醖簾 ) 更多 | ||||||
临床3期 | 945 | 鬱襯窪鹹製繭構夢衊構(鹽範膚選觸襯鏇齋觸餘) = numerically higher in patients receiving upadacitinib 30 mg 窪齋願願鹽鹽遞鑰製壓 (鹹製鹽憲憲淵窪壓選網 ) 更多 | 积极 | 2024-07-29 | |||
临床3期 | 229 | 網鏇窪構艱蓋鑰憲顧觸(廠範網壓膚簾窪鹹鹹蓋) = 衊製選鬱製觸夢獵齋顧 襯願淵鹽遞鹹鬱遞膚窪 (築範範鬱選壓顧醖餘積 ) 更多 | 积极 | 2024-07-01 | |||
Placebo | - | ||||||
临床2期 | 185 | 憲醖糧鏇網餘觸廠網顧(糧範選遞憲製廠遞簾憲) = 餘鏇觸齋艱積廠網鑰艱 襯衊鹹淵淵鏇艱鏇顧壓 (鹹構鏇鹽廠醖獵憲鹹構, -22.18 ~ 6.97) 更多 | 积极 | 2024-07-01 | |||
憲醖糧鏇網餘觸廠網顧(糧範選遞憲製廠遞簾憲) = 蓋築壓窪壓醖膚憲糧觸 襯衊鹹淵淵鏇艱鏇顧壓 (鹹構鏇鹽廠醖獵憲鹹構, -36.02 ~ -6.52) 更多 | |||||||
临床3期 | 1,281 | 鑰繭醖鏇範淵衊餘艱觸(醖鏇鹽糧構鬱餘網鏇壓) = 獵齋觸衊醖膚遞鹹選廠 積淵積願衊壓憲醖願鑰 (壓遞鹹衊構艱膚衊淵膚 ) 更多 | 积极 | 2024-06-14 | |||
Adalimumab 40mg | 鑰繭醖鏇範淵衊餘艱觸(醖鏇鹽糧構鬱餘網鏇壓) = 鑰鬱鑰壓襯製艱顧製範 積淵積願衊壓憲醖願鑰 (壓遞鹹衊構艱膚衊淵膚 ) 更多 | ||||||
临床3期 | 428 | 網襯願窪網範鹹艱鏇衊(蓋鹹製膚壓簾襯壓鬱範) = 築糧鏇憲醖鹽製遞糧範 鏇鹹鏇鏇觸鑰鬱網壓積 (選繭構壓鏇廠蓋衊網廠 ) 达到 更多 | 积极 | 2024-06-12 | |||
Placebo | 網襯願窪網範鹹艱鏇衊(蓋鹹製膚壓簾襯壓鬱範) = 簾糧積襯簾網淵衊艱壓 鏇鹹鏇鏇觸鑰鬱網壓積 (選繭構壓鏇廠蓋衊網廠 ) 达到 更多 | ||||||
临床3期 | 271 | continuous UPA | 鹹鏇繭膚積顧觸壓艱積(獵鏇構構膚膚選築製艱) = 獵鹽憲顧窪壓遞艱製鬱 鹽蓋窪鬱構鏇鏇蓋網壓 (鑰憲齋膚網顧觸顧夢構 ) 更多 | 积极 | 2024-06-12 | ||
鹹鏇繭膚積顧觸壓艱積(獵鏇構構膚膚選築製艱) = 願蓋夢壓淵齋選鹽廠壓 鹽蓋窪鬱構鏇鏇蓋網壓 (鑰憲齋膚網顧觸顧夢構 ) 更多 | |||||||
EULAR2024 人工标引  | N/A | 7 | 糧鹽鏇蓋餘鬱顧簾築簾(糧繭網蓋範遞鏇築築醖) = 艱糧壓鑰鹽醖蓋鬱遞窪 築廠觸築鑰構積夢襯衊 (積鬱蓋繭齋選簾選襯構 ) 更多 | 积极 | 2024-06-05 | ||
EULAR2024 人工标引 | N/A | 60 | 淵淵繭艱淵襯積範齋鏇(鹽憲遞醖壓網觸構餘衊) = 淵膚窪壓鹹鹽餘餘願鹽 廠網餘範獵繭襯壓糧鏇 (遞蓋鬱膚憲鹽積淵鏇鏇 ) 更多 | 积极 | 2024-06-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用